Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)

Sponsor
Hoffmann-La Roche
Study ID
NCT01089413
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab \[Avastin\] treatment in patients with metastatic colorectal cancer. Data will be collected for approximately 34 months. The target sample size is \>300 patients.

Key Dates

First listed
Mar 18, 2010
Start date
Jan 31, 2010
Status verified
Nov 2015
Primary completion
Jun 30, 2013
Completion
Jun 30, 2013

Study Design

Enrollment
201 participants (actual)

Arms

  • Arm: Cohort

Primary Outcome Measure

Duration of Bevacizumab Treatment [ Time Frame: Baseline up to end of treatment (up to approximately 3 years) ]

Related Studies